Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline Review, H1 2017

  • ID: 4318719
  • Drug Pipelines
  • Region: Global
  • 118 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 3SBio Inc
  • Amgen Inc
  • CCM Duopharma Biotech Bhd
  • GlaxoSmithKline Plc
  • Novartis AG
  • PharmaEssentia Corp
  • MORE

Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline Review, H1 2017, provides an overview of the Anaemia in Chronic Kidney Disease (Renal Anaemia) (Hematological Disorders) pipeline landscape.

Renal anaemia is a disease in which the patient has an unusually low count of red blood cells. Renal is a term that means of the kidneys, so anaemia is often associated with kidney disease. This type of anaemia is caused by a lack of erythropoietin, a protein produced in the kidneys that helps to create red blood cells. Symptoms caused by renal anaemia include pale skin and gums, become short of breath, dizziness and inability to think clearly.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Anaemia in Chronic Kidney Disease (Renal Anaemia) (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anaemia in Chronic Kidney Disease (Renal Anaemia) (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Anaemia in Chronic Kidney Disease (Renal Anaemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 12, 8, 1, 1, 6, 1 and 1 respectively.

Anaemia in Chronic Kidney Disease (Renal Anaemia) (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Anaemia in Chronic Kidney Disease (Renal Anaemia) (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Anaemia in Chronic Kidney Disease (Renal Anaemia) (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Anaemia in Chronic Kidney Disease (Renal Anaemia) (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Anaemia in Chronic Kidney Disease (Renal Anaemia) (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Anaemia in Chronic Kidney Disease (Renal Anaemia) (Hematological Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Anaemia in Chronic Kidney Disease (Renal Anaemia) (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Anaemia in Chronic Kidney Disease (Renal Anaemia) (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3SBio Inc
  • Amgen Inc
  • CCM Duopharma Biotech Bhd
  • GlaxoSmithKline Plc
  • Novartis AG
  • PharmaEssentia Corp
  • MORE

Introduction
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Overview
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Companies Involved in Therapeutics Development
3SBio Inc
Aevi Genomic Medicine Inc
Akebia Therapeutics Inc
Amgen Inc
Bayer AG
Betta Pharmaceuticals Co Ltd
Biocad
CCM Duopharma Biotech Bhd
Chong Kun Dang Pharmaceutical Corp
CJ HealthCare Corp
Dong-A Socio Holdings Co Ltd
FibroGen Inc
GlaxoSmithKline Plc
Intas Pharmaceuticals Ltd
Japan Tobacco Inc
JCR Pharmaceuticals Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Myungmoon pharmaceutical Co Ltd
Novartis AG
Panacea Biotec Ltd
Pfizer Inc
PharmaEssentia Corp
PhytoHealth Corp
Pieris Pharmaceuticals Inc
Reliance Life Sciences Pvt Ltd
Xenetic Biosciences Inc
Zydus Cadila Healthcare Ltd
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Drug Profiles
BPI-5014B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
daprodustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
darbepoetin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
darbepoetin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
darbepoetin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
darbepoetin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
darbepoetin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
darbepoetin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
darbepoetin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
darbepoetin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EPO-018B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epoetin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epoetin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epoetin zeta biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ErepoXen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
erythropoietin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FG-2216 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HSA-EPO - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JTZ-951 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDGN-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MMP-0101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
molidustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PEG-EPO - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peg-EPO - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PEG-EPO - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegylated erythropoietin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PHEP-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRS-080 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Renal Anaemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
roxadustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SSS-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SSS-17 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vadadustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Dormant Projects
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Discontinued Products
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Product Development Milestones
Featured News & Press Releases
May 25, 2017: FDA Advisory Committee Recommends Approval Of Pfizer's Proposed Biosimilar To Epogen/Procrit Across All Indications
May 24, 2017: Akebia Initiates Phase 2 FO2RWARD Study of Vadadustat in Dialysis Patients with Anaemia Related to Chronic Kidney Disease Hyporesponsive to Treatment with Erythropoiesis-Stimulating Agents
Mar 30, 2017: Positive Results Published in Nephrology Dialysis Transplantation From Two China Phase 2 Trials of Roxadustat for Treatment of Anaemia in Chronic Kidney Disease
Mar 28, 2017: Akebia Announces Publication of Phase 2a Results for Vadadustat in Patients with Anaemia Related to Chronic Kidney Disease
Nov 24, 2016: GSK starts phase III programme with daprodustat for anaemia associated with chronic kidney disease
Oct 10, 2016: Xenetic Biosciences Reports Positive Topline Data from Third Cohort of Phase 2 Dose-Escalation Trial of ErepoXen for Anaemia
Sep 26, 2016: Akebia Announces Publication Highlighting Potential Benefits of HIF Treatments for Patients with Renal Anaemia
Sep 19, 2016: Akebia Announces Publication of Phase 2b Data for Vadadustat in Non-Dialysis Patients with Anaemia Related to Chronic Kidney Disease
Aug 22, 2016: Akebia Announces Publication Highlighting Need for New Solutions in Treating Dialysis Patients
Aug 09, 2016: Kissei and JCR to Initiate a Phase III Clinical Trial of a Long-Acting Erythropoiesis-Stimulating Agent (Development Code: JR-131)
Aug 08, 2016: Akebia Initiates INNO2VATE Phase 3 Program for Vadadustat in Dialysis Patients With Anaemia Related to Chronic Kidney Disease
Jul 25, 2016: Astellas And Fibrogen Announce First Patient Treated In Phase 3 Studies And Positive Phase 2 Results Of Roxadustat In Patients With Chronic Kidney Disease In Japan
Jun 09, 2016: Fibrogen Announces Initiation By Astellas Of Phase 3 Clinical Study In Japan Of Roxadustat/ASP1517 For The Treatment Of Anaemia Of Chronic Kidney Disease Triggering $10.0 Million Milestone Payment
May 23, 2016: Akebia Announces Positive Vadadustat Data Demonstrating No Clinically Significant Drug-Drug Interaction
May 05, 2016: Akebia Provides Update On Phase 3 INNO2VATE Program For Vadadustat
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Anaemia in Chronic Kidney Disease (Renal Anaemia), H1
Number of Products under Development by Companies, H1
Number of Products under Development by Companies, H1 2017 (Contd..1), H1
Products under Development by Companies, H1
Products under Development by Companies, H1 2017 (Contd..1), H1
Products under Development by Companies, H1 2017 (Contd..2), H1
Number of Products by Stage and Target, H1
Number of Products by Stage and Mechanism of Action, H1
Number of Products by Stage and Route of Administration, H1
Number of Products by Stage and Molecule Type, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by 3SBio Inc, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Aevi Genomic Medicine Inc, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Akebia Therapeutics Inc, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Amgen Inc, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Bayer AG, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Betta Pharmaceuticals Co Ltd, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Biocad, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by CCM Duopharma Biotech Bhd, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by CJ HealthCare Corp, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Dong-A Socio Holdings Co Ltd, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by FibroGen Inc, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by GlaxoSmithKline Plc, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Intas Pharmaceuticals Ltd, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Japan Tobacco Inc, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by JCR Pharmaceuticals Co Ltd, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Myungmoon pharmaceutical Co Ltd, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Novartis AG, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Panacea Biotec Ltd, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Pfizer Inc, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by PharmaEssentia Corp, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by PhytoHealth Corp, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Pieris Pharmaceuticals Inc, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Reliance Life Sciences Pvt Ltd, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Xenetic Biosciences Inc, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Zydus Cadila Healthcare Ltd, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Dormant Projects, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Discontinued Products, H1

List of Figures
Number of Products under Development for Anaemia in Chronic Kidney Disease (Renal Anaemia), H1
Number of Products under Development by Companies, H1
Number of Products by Targets, H1
Number of Products by Stage and Targets, H1
Number of Products by Mechanism of Actions, H1
Number of Products by Stage and Mechanism of Actions, H1
Number of Products by Routes of Administration, H1
Number of Products by Stage and Routes of Administration, H1
Number of Products by Molecule Types, H1
Number of Products by Stage and Molecule Types, H1

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 3SBio Inc
  • Aevi Genomic Medicine Inc
  • Akebia Therapeutics Inc
  • Amgen Inc
  • Bayer AG
  • Betta Pharmaceuticals Co Ltd
  • Biocad
  • CCM Duopharma Biotech Bhd
  • Chong Kun Dang Pharmaceutical Corp
  • CJ HealthCare Corp
  • Dong-A Socio Holdings Co Ltd
  • FibroGen Inc
  • GlaxoSmithKline Plc
  • Intas Pharmaceuticals Ltd
  • Japan Tobacco Inc
  • JCR Pharmaceuticals Co Ltd
  • Jiangsu Hansoh Pharmaceutical Group Co Ltd
  • Myungmoon pharmaceutical Co Ltd
  • Novartis AG
  • Panacea Biotec Ltd
  • Pfizer Inc
  • PharmaEssentia Corp
  • PhytoHealth Corp
  • Pieris Pharmaceuticals Inc
  • Reliance Life Sciences Pvt Ltd
  • Xenetic Biosciences Inc
  • Zydus Cadila Healthcare Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll